Commerzbank restated their buy rating on shares of Qiagen (NASDAQ:QGEN) in a research report sent to investors on Friday, January 19th.
A number of other equities analysts have also recently weighed in on QGEN. Cowen restated a hold rating and issued a $33.00 price target on shares of Qiagen in a report on Thursday, September 28th. Zacks Investment Research upgraded Qiagen from a hold rating to a buy rating and set a $39.00 price target for the company in a report on Tuesday, October 10th. JPMorgan Chase & Co. restated a neutral rating on shares of Qiagen in a report on Tuesday, November 7th. Deutsche Bank reiterated a buy rating on shares of Qiagen in a research note on Wednesday, November 8th. Finally, TheStreet upgraded Qiagen from a c+ rating to a b+ rating in a research note on Tuesday, November 7th. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $35.33.
Qiagen (NASDAQ QGEN) traded up $0.11 on Friday, reaching $31.92. 961,184 shares of the company were exchanged, compared to its average volume of 1,492,161. The firm has a market cap of $7,260.12, a P/E ratio of 187.78, a PEG ratio of 1.93 and a beta of 1.03. Qiagen has a 12-month low of $27.74 and a 12-month high of $36.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07.
Qiagen announced that its Board of Directors has authorized a stock buyback program on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC increased its position in Qiagen by 816.3% in the fourth quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock worth $32,529,000 after buying an additional 936,936 shares during the period. American International Group Inc. acquired a new position in shares of Qiagen during the fourth quarter valued at $154,000. Systematic Financial Management LP acquired a new position in shares of Qiagen during the fourth quarter valued at $15,834,000. Wells Fargo & Company MN increased its holdings in shares of Qiagen by 44.1% during the fourth quarter. Wells Fargo & Company MN now owns 124,743 shares of the company’s stock valued at $3,859,000 after purchasing an additional 38,149 shares during the period. Finally, Bronfman E.L. Rothschild L.P. increased its holdings in shares of Qiagen by 50.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock valued at $354,000 after purchasing an additional 3,860 shares during the period. 62.23% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Qiagen’s (NASDAQ:QGEN) “Buy” Rating Reaffirmed at Commerzbank” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/12/qiagen-qgen-rating-reiterated-by-commerzbank.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.